Art. -Nr.: HY-19718

OTS964

13 Cited Publications

Kundenbewertung

Based on 13 publication(s) in Google Scholar

OTS964 is an orally active, high affinity and selective TOPK inhibitor with an IC₅₀ of 28 nM. OTS964 is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a K_d of 40 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 1338542-14-5
Formel: C₂₃H₂₄N₂O₂S
Molecular Weight:392.51

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (278 KB)

OTS964 Chemical Structure

CAS. Nr.: 1338542-14-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (13)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

OTS964 is an orally active, high affinity and selective TOPK inhibitor with an IC₅₀ of 28 nM^[1]. OTS964 is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a K_d of 40 nM^[2].

IC₅₀ & Target^[1]^[2]

TOPK

28 nM (IC₅₀)

CDK11B

40 nM (Kd)

Alle CDK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	20.41 nM Compound: OTS964	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30453248]
A549	IC₅₀	31 nM Compound: OTS964	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
CWR22R	IC₅₀	50 nM Compound: OTS964	Cytotoxicity against human 22Rv1 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human 22Rv1 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
Daudi	IC₅₀	25 nM Compound: OTS964	Cytotoxicity against human Daudi cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human Daudi cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
DU-4475	IC₅₀	53 nM Compound: OTS964	Cytotoxicity against human DU4475 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human DU4475 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
HCT-116	IC₅₀	33 nM Compound: OTS964	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
HCT-116	IC₅₀	45 nM Compound: OTS964	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30453248]
HCT-15	IC₅₀	73.08 nM Compound: OTS964	Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 30453248]
HepG2	IC₅₀	19 nM Compound: OTS964	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
Lu-99 cell line	IC₅₀	7.6 nM Compound: OTS964	Cytotoxicity against human LU99 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human LU99 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
MDA-MB-231	IC₅₀	73 nM Compound: OTS964	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
MIA PaCa-2	IC₅₀	30 nM Compound: OTS964	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
MKN-1	IC₅₀	38 nM Compound: OTS964	Cytotoxicity against human MKN1 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MKN1 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
MKN-45	IC₅₀	39 nM Compound: OTS964	Cytotoxicity against human MKN45 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MKN45 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
T47D	IC₅₀	72 nM Compound: OTS964	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]
UMUC3	IC₅₀	32 nM Compound: OTS964	Cytotoxicity against human UM-UC-3 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human UM-UC-3 cells assessed as decrease in cell viability after 72 hrs by CCK8 assay	[PMID: 30108692]

In Vitro

OTS964 (10 nM; 48 hours) suppresses cancer cell proliferation^[1].
OTS964 (10 nM; 48 hours) increases cancer cell death^[1].
OTS964 (0.1-2 μM; 24 and 48 hours) increases the expression of LC3-II and decreases the expression of P62, both in a dose-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

LU-99 cells
Concentration:

10 nM
Incubation Time:

48 hours
Result:

Suppressed cancer cell proliferation.

Apoptosis Analysis^[1]

Cell Line:

LU-99 cells
Concentration:

10 nM
Incubation Time:

48 hours
Result:

Increased cancer cell death.

Western Blot Analysis^[3]

Cell Line:

Hs683 cells, H4 cells
Concentration:

0.1, 1, 2 μM
Incubation Time:

24 and 48 hours
Result:

Increased the expression of LC3-II and decreased the expression of P62, both in a dose-dependent manner.

In Vivo

OTS964 (intravenously; 40 mg/kg on days 1, 4, 8, 11, 15, and 18) makes tumors shrinking even after the treatment and finally revealing complete regression^[1].
OTS964 (oral administration; 50 or 100 mg/kg/day for 2 weeks) achieves complete tumor regression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Nude mice bearing LU-99 lung cancer cells^[1]
Dosage:

40 mg/kg
Administration:

Intravenously; on days 1, 4, 8, 11, 15, and 18
Result:

The tumors continued shrinking even after the treatment and finally revealed complete regression.

Animal Model:

Nude mice bearing LU-99 lung cancer cells^[1]
Dosage:

50 or 100 mg/kg
Administration:

Oral administration; once every day for 2 weeks
Result:

Achieved complete tumor regression.

Chemical Information

CAS. Nr. 1338542-14-5
Molecular Weight 392.51
Formel C₂₃H₂₄N₂O₂S
SMILES

O=C(N1)C2=C(C=CS2)C3=C1C(C)=CC(O)=C3C4=CC=C([C@@H](C)CN(C)C)C=C4
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (13)

All WBCell Proliferation/Viability AssayFlow Cytometry

Sort by:

Journal Impact Factor

Nature

CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1. [Abstract]

2022 Sep;609(7928):829-834. PMID: 36104565

OTS964 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Sep;609(7928):829-834. [Abstract]

OTS964 hydrochloride (0, 10, 30, 100, 250, 500, 2000 nM; 4 h) decreased the total RNAPII^CTD phosphorylation at Tyr1, Ser2, Thr4, Ser5 and Ser7 in HCT116 cells.
Cell

The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. [Abstract]

2021 Jun 10;184(12):3143-3162.e32. PMID: 34004147
Mol Cell

A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation. [Abstract]

2025 Sep 4;85(17):3256-3274.e14. PMID: 40858114

OTS964 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2025 Sep 4;85(17):3256-3274.e14. [Abstract]

OTS964 hydrochloride (0-1000 nM; 48 h) dose-dependent increases in cell death in THP1 and MV4;11 cells.

OTS964 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2025 Sep 4;85(17):3256-3274.e14. [Abstract]

OTS964 hydrochloride (39 nM; 24 h) induced cell cycle arrest at G1 phase in THP1 FUCCI cells.
Adv Sci (Weinh)

Zygotic Splicing Activation of the Transcriptome is a Crucial Aspect of Maternal-to-Zygotic Transition and Required for the Conversion from Totipotency to Pluripotency. [Abstract]

2024 Apr;11(14):e2308496. PMID: 38308190
Cell Death Dis

TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ. [Abstract]

2019 Aug 5;10(8):583. PMID: 31378785

OTS964 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Aug 5;10(8):583. [Abstract]

OTS964 hydrochloride (0, 0.1, 1, 2 μM; 24, 48 h) inhibited cells viability and increased the expression of LC3-II and decreased the expression of P62, and both were in a dose-dependent manner in Hs683 cells.

OTS964 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Aug 5;10(8):583. [Abstract]

OTS964 hydrochloride (0, 0.1, 1, 2 μM; 24, 48 h) inhibited cells viability and increased the expression of LC3-II and decreased the expression of P62, and both were in a dose-dependent manner in H4 cells.

OTS964 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Aug 5;10(8):583. [Abstract]

OTS964 hydrochloride (1 μM; 48 h) activated autophagy initiation without affecting autophagic flux in Hs683 (left) and H4 (right) cells. Baf A1 (50 nM) was added 5 h before the cells were harvested.

OTS964 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Aug 5;10(8):583. [Abstract]

OTS964 hydrochloride (0, 0.1, 1, 2 μM; 48 h) increased the expression of ULK1 and the levels of p-ATG13 and p-Beclin-1 in a dose-dependent manner in Hs683 (left) and H4 (right) cells.
J Eur Acad Dermatol Venereol

TOPK promotes the development of psoriasis and worenine alleviates psoriasiform dermatitis by inhibiting TOPK activity. [Abstract]

2024 May;38(5):851-863. PMID: 38131517
Mol Cell Proteomics

Proteomics and Phosphoproteomics Revealed Dysregulated Kinases and Potential Therapy for Liver Fibrosis. [Abstract]

2025 May 12:100991. PMID: 40368138
Cancers (Basel)

Targeting CDK11 in Rhabdoid Tumor of the Kidney. [Abstract]

2026 Jan 14;18(2):261. PMID: 41595181
iScience

TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1. [Abstract]

2023 Jun 20;26(7):107185. PMID: 37404377
bioRxiv

2026 Mar 26.
bioRxiv

2025 Nov 20.
bioRxiv

2025 Sep 28.
SSRN

2022 Nov 21.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Matsuo Y , et al. TOPK inhibitor induces complete tumor regression in xenograft models of human cancerthrough inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22;6(259):259ra145. [Content Brief]

[2]. Lin A, et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019 Sep 11;11(509). [Content Brief]

[3]. Lu H, et al. TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ. Cell Death Dis. 2019 Aug 5;10(8):583. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

OTS964

13 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

OTS964

Publications Citing Use of MedChemExpress (MCE) OTS964

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

OTS964 Related Classifications

HY-19718 Related Classifications